Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags MORAb-202

Tag: MORAb-202

Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...

ADC Review | Editorial Team
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...

MORAb-202 has Potential Anti-tumor Effects in Breast Cancer

ADC Review | Editorial Team
MORAb-202, Eisai’s first antibody-drug conjugate, targets FRα-positive solid tumors. The investigational agent is composed of the company’s in-house developed anticancer agent farletuzumab, a humanized...

First Patient Dosed in Phase I Dose-escalation Study with MORAb-202

Peter Hofland
A first patient has been enrolled into a Phase I cancer study of the novel investigational antibody-drug conjugate MORAb-202, being developed by Morphotek, a...

8th World ADC: Morphotek to Present Preclinical Data on MORAb-202

Peter Hofland
During the upcoming 8th Annual World ADC being held September 20-22, 2017 at the Sheraton San Diego Marina in San Diego, CA, Morphotek®, a...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X